The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Hospital data reveals a sharp rise in consultations related to hormonal health, erectile dysfunction and male fertility, highlighting growing awareness among younger men.
CEO Stéphane Bancel framed the changes as essential to scaling the business
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
